Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenocarcinoma
Study data from L. Dilauro et al provide new insights into adenocarcinoma
May 12th, 2009
"This phase II study was designed to evaluate the activity and safety of a combination of epirubicin, oxaliplatin and docetaxel in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Forty patients with measurable distant metastases received epirubicin 50 mg/m(2), docetaxel 60 mg/m(2) followed by oxaliplatin 100 mg/m(2) on day 1 of each 21-day cycle," scientists in Rome, Italy report. "Primary end point was response rates (RR). All patients were evaluable. The overall RR was 47.5% (95% confidence interval (CI) 32 63). The disease control was 80%. Median time for response was 6 weeks. Median time to progression was 6.3 months (95% CI 5.4-7.2) and the...
Source: Cancer Weekly (2009-05-12)
|
